Poster presented at AAPS PharmSci 360 2024 Salt Lake City, on joint research with Queen's University Belfast on Lumefantrine prior to publishing our full paper

Over the last 15 years, a small number of paediatric artemisinin-based combination therapy products have been  marketed. These included Riamet® and Coartem® dispersible tablets, a combination of artemether and lume fantrine, co-developed by the Medicines for Malaria Venture and Novartis. Disappointingly, patient compliance,  requirement for high-fat meal, and sporadic drug dissolution behaviours following administration still result in  considerable challenges for these products. (Joint research between Rondol and Queens' University Belfast)

Poster presented at PBP Vienna in 2024, prior to the publication of our paper on Lumefantrine.

This paper aims to give an overview of our current research and development on hot-melt extrusion (HME) for pharmaceutical formulation and drug delivery. Unfortunately, a large percentage of marketed drugs (40%) and those in the  development pipeline (90%) are poorly water soluble. We use a few examples to  show that solubility of APIs can be drastically improved by using HME to mix  them with different biocompatible polymers and playing with the various process parameters (extrusion temperature, screw speed, screw configuration, etc.).

New trends in the food industry are radically transforming how we produce, process, and consume food, creating new pathways  for personalization, sustainability, and operational efficiency. Vertical Hot Melt Extrusion (HME) is a major innovation that  offers unprecedented opportunities to create highly personalized food products tailored to specific dietary needs or remote  locations, including nutrient-dense options designed for individual health requirements.